BEAT vs HSDT vs IDXX vs LIVN vs NVCR

For growth investors, Solana Company (HSDT) is the stronger pick with 1057% revenue growth year-over-year, versus 8.

3% for NovoCure Limited (NVCR). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 42. 8x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, LivaNova PLC is actually cheaper at 16.

9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +6. 6%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HeartBeam, Inc.

(BEAT) is the lower-risk stock at 1. 27β versus Solana Company's 2. 65β — meaning HSDT is approximately 108% more volatile than BEAT relative to the S&P 500. On balance sheet safety, LivaNova PLC (LIVN) carries a lower debt/equity ratio of 39% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Solana Company (HSDT) is pulling ahead at 1057% versus 8.

3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57. 3% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, HSDT leads at 97. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -679. 6% for Solana Company — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, LivaNova PLC (LIVN) trades at 16.

9x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 21. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). Solana Company (HSDT) carries a higher beta of 2. 65 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BEAT is a small-cap quality compounder stock; HSDT is a small-cap high-growth stock; IDXX is a mid-cap quality compounder stock; LIVN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.